Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Esophagus Cancer
Interventions
DRUG

Cadonilimab

Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.

DRUG

Paclitaxel and cisplatin

Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.

RADIATION

intensity-modulated radiotherapy

All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.

Trial Locations (1)

510060

Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER